However when exploring the potential effects of a SETD2 mutation on homologous recombination pathways, we observed a decreased HRD score in the SETD2 mut + group compared to the SETD2 mut- group in endometrial carcinoma, colorectal adenocarcinoma, and stomach adenocarcinoma. The gene discussed is SETD2; the disease is endometrial carcinoma.